- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Xenograft.
Displaying page 1 of 1.
| EudraCT Number: 2018-002988-25 | Sponsor Protocol Number: ML-DS2018 | Start Date*: Information not available in EudraCT |
| Sponsor Name:Gesellschaft für Pädiatrische Onkologie & Hämatologie (GPOH gGmbH) | ||
| Full Title: Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 | ||
| Medical condition: Myeloid Leukemia in Children with Down Syndrome | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) NL (Ongoing) AT (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-000618-39 | Sponsor Protocol Number: Sym004-13 | Start Date*: 2018-10-23 |
| Sponsor Name:Symphogen A/S | ||
| Full Title: A Phase 2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 versus each of its Component Monoclonal Antibodies, Futuximab and Modotuximab, in Patients with Chemotherapy-Refractory Met... | ||
| Medical condition: Metastatic Colorectal Carcinoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-003429-32 | Sponsor Protocol Number: ImbruVeRCHOP-Trial | Start Date*: 2017-02-09 |
| Sponsor Name:Charité - Universitätsmedizin Berlin | ||
| Full Title: “Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2” | ||
| Medical condition: untreated CD20-positive DLBCL-like aggressive Non-Hodgkin’s lymphoma, 61-80 years of age with unfavorable risk profile (IPI ≥ 2) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-004623-36 | Sponsor Protocol Number: MEGALiT1901 | Start Date*: 2019-11-29 |
| Sponsor Name:Uppsala University Hospital | ||
| Full Title: A MolEcularly Guided Anti-Cancer Drug Off-Label Trial – a multicenter, basket and umbrella explorative trial on the efficacy and safety of molecular profile selected commercially available targete... | ||
| Medical condition: In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-003319-12 | Sponsor Protocol Number: ICR-CTSU-2014-10046 | Start Date*: 2015-03-27 | |||||||||||
| Sponsor Name:The Royal Marsden NHS Foundation Trust [...] | |||||||||||||
| Full Title: Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO) | |||||||||||||
| Medical condition: Primary breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-014136-37 | Sponsor Protocol Number: Thal-002 | Start Date*: 2010-07-13 | |||||||||||||||||||||
| Sponsor Name:University of Washington | |||||||||||||||||||||||
| Full Title: A pilot study on the safety and efficacy of haemopoietic stem cell mobilization (CD34+ cells) with MOZOBIL ± G-CSF, in adult patients diagnosed with beta-thalassaemia major. | |||||||||||||||||||||||
| Medical condition: Beta-thalassaemia major | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GR (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2014-005066-30 | Sponsor Protocol Number: RG_14-088 | Start Date*: 2018-03-20 | |||||||||||
| Sponsor Name:The University of Birmingham | |||||||||||||
| Full Title: MyeChild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with ... | |||||||||||||
| Medical condition: Newly diagnosed acute myeloid leukaemia (AML), high risk myelodysplastic syndrome(MDS) and isolated myeloid sarcoma (either de novo or secondary) are eligible for the trial. | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
